Analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings of ($0.71) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Crispr Therapeutics’ earnings, with estimates ranging from ($0.77) to ($0.64). Crispr Therapeutics posted earnings per share of ($0.40) during the same quarter last year, which indicates a negative year-over-year growth rate of 77.5%. The company is expected to issue its next quarterly earnings report on Friday, March 9th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($2.42) per share for the current year, with EPS estimates ranging from ($2.49) to ($2.35). For the next financial year, analysts forecast that the firm will post earnings of ($2.83) per share, with EPS estimates ranging from ($3.08) to ($2.38). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Crispr Therapeutics.
Several research firms recently weighed in on CRSP. Piper Jaffray Companies restated a “buy” rating and set a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday, January 10th. Citigroup boosted their price target on shares of Crispr Therapeutics from $20.00 to $51.00 and gave the stock a “neutral” rating in a report on Wednesday. Oppenheimer restated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, December 21st. SunTrust Banks restated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $28.45.
Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the period. Vanguard Group Inc. bought a new stake in shares of Crispr Therapeutics in the second quarter valued at approximately $273,000. Ark Investment Management LLC bought a new stake in shares of Crispr Therapeutics in the second quarter valued at approximately $206,000. Capital Investment Advisory Services LLC bought a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $193,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $344,000. 24.55% of the stock is currently owned by institutional investors.
Crispr Therapeutics (NASDAQ CRSP) traded up $3.48 during trading on Friday, reaching $50.02. 1,113,548 shares of the company traded hands, compared to its average volume of 1,070,000. Crispr Therapeutics has a 1-year low of $13.50 and a 1-year high of $51.00. The stock has a market capitalization of $2,300.00 and a PE ratio of -156.31.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.